Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.86 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.41 |
| ▸ | ABAT | P80404 | 1/20 | 0.41 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195687 | 0.93 | ALDH1A1 (1.00) | ALDH1A1CYP2A6FBP1CYP1A1CYP1A2 | |
| SCHEMBL19914058 | 0.86 | ALDH1A1 (0.86) | ALDH1A1CYP2A6FBP1CYP1A1CYP1A2 | |
| SCHEMBL21738358 | 0.81 | ALDH1A1 (0.76) | ALDH1A1CYP2A6FBP1CYP1A1CYP1A2 | |
| SCHEMBL28538380 | 0.81 | ALDH1A1 (0.76) | ALDH1A1CYP2A6FBP1CYP1A1CYP1A2 | |
| SCHEMBL9264469 | 0.81 | ALDH1A1 (0.76) | ALDH1A1CYP2A6FBP1CYP1A1CYP1A2 | |
| SCHEMBL21770156 | 0.81 | ALDH1A1 (0.57) | ALDH1A1CYP2A6DRD1PTGS2AKR1C3 | |
| SCHEMBL25288128 | 0.80 | CYP2A6 (0.58) | ALDH1A1CYP2A6DRD1TYRCYP2A13 | |
| SCHEMBL10300271 | 0.80 | ALDH1A1 (0.50) | ALDH1A1PTGS2HAO1 | |
| SCHEMBL976904 | 0.80 | CYP2A6 (0.58) | ALDH1A1CYP2A6DRD1TYRCYP2A13 | |
| SCHEMBL1666706 | 0.80 | CYP2A6 (0.58) | ALDH1A1CYP2A6DRD1TYRCYP2A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3720840-B1 | CATHEPSIN INHIBITORS | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2022-01-19 | — | — | EP | disclosed |
| US-20150087498-A1 | Production of Graphene and Nanoparticle Catalysts Supported on Graphene Using Microwave Radiation | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-03-26 | — | — | US | disclosed |
| US-8871171-B2 | Production of graphene and nanoparticle catalysts supported on graphene using microwave radiation | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130211106-A1 | PRODUCTION OF GRAPHENE AND NANOPARTICLE CATALYSTS SUPPORTED ON GRAPHENE USING MICROWAVE RADIATION | NATIONAL SCIENCE FOUNDATION | 2013-08-15 | — | — | US | disclosed |
| US-8507726-B2 | Photoinitiator mixtures | BASF SE (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20110218266-A1 | PHOTOINITIATOR MIXTURES | BASF SE (DE) | 2011-09-08 | — | — | US | disclosed |
| EP-2342237-A1 | PHOTOINITIATOR MIXTURES | BASF SE (DE) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010060702-A1 | PHOTOINITIATOR MIXTURES | BASF SE (DE) | 2010-06-03 | — | — | WO | disclosed |
| US-7462620-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM, PLC (GB) | 2008-12-09 | — | — | US | disclosed |
| EP-1337517-B1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2008-11-26 | — | — | EP | disclosed |
| US-7169924-B2 | Pyrimidinone derivatives and their use in the treatment of atherosclerosis | SMITHKLINE BEECHAM PLC (GB) | 2007-01-30 | — | — | US | disclosed |
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | ELLIOTT RICHARD L | 2006-10-26 | — | — | US | disclosed |
| EP-1337517-A1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002030911-A1 | PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241126-A1 | Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis | PLA2G7, PLA2G1B, PLA2G4B | ALDH1A1 505/4885CYP2A6 1091/4885FBP1 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.